Daniel Horber

436 total citations
21 papers, 325 citations indexed

About

Daniel Horber is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Horber has authored 21 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Horber's work include Colorectal Cancer Treatments and Studies (5 papers), Glycosylation and Glycoproteins Research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Daniel Horber is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Glycosylation and Glycoproteins Research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Daniel Horber collaborates with scholars based in Switzerland, Germany and Hungary. Daniel Horber's co-authors include Herbert Schott, Reto A. Schwendener, R.A. Schwendener, Dieter Koeberle, Karin Ribi, Michael Montemurro, Piercarlo Saletti, Cornelia Ottiger, Gyula Demeter and Jonas Feilchenfeldt and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Daniel Horber

21 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Horber Switzerland	12	154	119	82	67	52	21	325
Masako Yokoo Japan	8	103 0.7×	102 0.9×	78 1.0×	47 0.7×	28 0.5×	26	365
Patrizia Nardulli Italy	12	136 0.9×	200 1.7×	39 0.5×	29 0.4×	65 1.3×	20	408
David D. Gibbs New Zealand	8	198 1.3×	213 1.8×	24 0.3×	35 0.5×	58 1.1×	15	514
Nienke Losekoot Netherlands	11	217 1.4×	160 1.3×	17 0.2×	24 0.4×	54 1.0×	14	400
Olaf H. Temmink Netherlands	12	226 1.5×	348 2.9×	28 0.3×	51 0.8×	67 1.3×	14	534
C. Papadimitriou Greece	9	203 1.3×	241 2.0×	100 1.2×	14 0.2×	85 1.6×	16	513
Akio Fujioka Japan	13	206 1.3×	362 3.0×	39 0.5×	72 1.1×	54 1.0×	21	518
Abdurahman Alloghbi United States	7	317 2.1×	183 1.5×	54 0.7×	44 0.7×	91 1.8×	19	589
Xianglei Yan China	13	228 1.5×	148 1.2×	17 0.2×	46 0.7×	57 1.1×	23	428
Kornelia Aigner Germany	8	158 1.0×	169 1.4×	26 0.3×	35 0.5×	43 0.8×	29	385

Countries citing papers authored by Daniel Horber

Since Specialization

Citations

This map shows the geographic impact of Daniel Horber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Horber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Horber more than expected).

Fields of papers citing papers by Daniel Horber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Horber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Horber. The network helps show where Daniel Horber may publish in the future.

Co-authorship network of co-authors of Daniel Horber

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Horber. A scholar is included among the top collaborators of Daniel Horber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Horber. Daniel Horber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2025). Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clinical Cancer Research. 31(15). 3142–3149. 1 indexed citations

Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2024). 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. Annals of Oncology. 35. S432–S432. 5 indexed citations

Glatzer, Markus, Daniel Horber, Michael Montemurro, et al.. (2020). Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology. 20(4). 686–690. 9 indexed citations

Kienle, Dirk, Daniel Dietrich, Karin Ribi, et al.. (2018). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology. 10(2). 304–310. 17 indexed citations

Fehr, Martin, Joachim Müller, Jürgen Fornaro, et al.. (2017). Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clinical Colorectal Cancer. 16(4). 343–348. 3 indexed citations

Quagliata, Luca, Mariacarla Andreozzi, Serenella Eppenberger‐Castori, et al.. (2017). Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS ONE. 12(4). e0175563–e0175563. 15 indexed citations

Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology. 27(5). 856–861. 102 indexed citations

Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2014). Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).. Journal of Clinical Oncology. 32(15_suppl). 4099–4099. 3 indexed citations

Tarantino, Ignazio, Ulrich Güller, Alexis Ulrich, et al.. (2013). Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients. Annals of Surgical Oncology. 20(12). 3877–3884. 17 indexed citations

10.

Horber, Daniel, et al.. (2000). Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N 4 -alkyl-1-β- D -arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5′ → 5′)- N 4 -octadecyl-1-β- d -arabinofuranosylcytosine. Journal of Cancer Research and Clinical Oncology. 126(6). 311–319. 17 indexed citations

11.

Horber, Daniel, et al.. (1997). Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. British Journal of Cancer. 75(7). 986–992. 19 indexed citations

12.

Schwendener, Reto A., Daniel Horber, B Odermatt, & Herbert Schott. (1996). Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-?-d-arabinofuranosylcytosine. Journal of Cancer Research and Clinical Oncology. 122(2). 102–108. 18 indexed citations

13.

Horber, Daniel, Cornelia Ottiger, Herbert Schott, & Reto A. Schwendener. (1995). Pharmacokinetic Properties and Interactions with Blood Components of N4-Hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) Incorporated into Liposomes. Journal of Pharmacy and Pharmacology. 47(4). 282–288. 16 indexed citations

14.

Horber, Daniel, Herbert Schott, & Reto A. Schwendener. (1995). Cellular pharmacology ofN 4-hexadecyl-1-?-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemotherapy and Pharmacology. 36(6). 483–492. 14 indexed citations

15.

Horber, Daniel, Peter von Ballmoos, Herbert Schott, & R.A. Schwendener. (1995). Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine. British Journal of Cancer. 72(5). 1067–1073. 22 indexed citations

16.

Schwendener, Reto A., Daniel Horber, Cornelia Ottiger, & Herbert Schott. (1995). Preclinical Properties of N⁴-Hexadecyl- and N⁴- Octadecyl-1-β-D-Arabinofuranosylcytosine in Liposomal Preparations. Journal of Liposome Research. 5(1). 27–47. 13 indexed citations

17.

Horber, Daniel, Peter von Ballmoos, Herbert Schott, & Reto A. Schwendener. (1995). Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-cytosine arabinoside (NHAC), a new lipophilic derivative of cytosine arabinoside. Journal of Cancer Research and Clinical Oncology. 121(S1). A2–A2. 1 indexed citations

18.

Schwendener, R.A., et al.. (1994). New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Research. 24(1). 79–93. 12 indexed citations

19.

Schwendener, Reto A., et al.. (1994). Preclinical and Clinical Experience with Liposome-Encapsulated Mitoxantrone. Journal of Liposome Research. 4(1). 605–639. 10 indexed citations

20.

Schott, Herbert, et al.. (1994). Synthesis, and Some Properties of, Amphiphilic Dinucleoside Phosphate Derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT). Antiviral chemistry & chemotherapy. 5(6). 387–394. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact